How can I determine if my gastritis is atrophic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Determine if Gastritis is Atrophic

The diagnosis of atrophic gastritis must be confirmed by histopathology from gastric biopsies, regardless of clinical suspicion or endoscopic findings. 1

Diagnostic Approach

Endoscopic Recognition

During upper endoscopy, look for these characteristic features of atrophic gastritis: 1

  • Pale appearance of the gastric mucosa
  • Increased visibility of submucosal vasculature due to mucosal thinning
  • Loss of gastric folds
  • If intestinal metaplasia is present: light blue crests and white opaque fields

Important caveat: These mucosal changes are often subtle and can be easily missed without careful examination and optimal visualization techniques. 1

Biopsy Strategy

When endoscopic features suggest atrophic gastritis, obtain biopsies systematically: 1

  • Minimum requirement: Biopsies from both the gastric body and antrum/incisura, placed in separately labeled jars
  • Take targeted biopsies from any additional mucosal abnormalities
  • This topographic approach allows determination of the extent and distribution of atrophy

Histopathologic Confirmation

Atrophic gastritis is defined as loss of gastric glands, with or without metaplasia, in the setting of chronic inflammation. 1 The pathologist will grade the severity and extent of atrophy.

Critical point: If your pathology report shows intestinal metaplasia, this almost invariably implies underlying atrophic gastritis, even if atrophy is not explicitly mentioned in the report. 1 You should coordinate with your pathologist to ensure consistent documentation of atrophy severity when intestinal metaplasia is present.

Determining the Etiology

Test for H. pylori

All patients with atrophic gastritis must be assessed for Helicobacter pylori infection: 1

  • Use non-serological testing (stool antigen, urea breath test, or biopsy-based methods)
  • If positive, treat and confirm eradication with non-serological testing
  • H. pylori-associated atrophic gastritis typically shows antral-predominant or pangastric distribution 1

Evaluate for Autoimmune Gastritis

If histology shows corpus-predominant atrophy (sparing the antrum), consider autoimmune gastritis: 1

Serologic testing:

  • Anti-parietal cell antibodies
  • Anti-intrinsic factor antibodies

Laboratory evaluation:

  • Vitamin B12 levels (deficiency indicates advanced disease)
  • Iron studies (iron deficiency is common)
  • Complete blood count (look for macrocytic anemia from B12 deficiency or microcytic anemia from iron deficiency) 1

Non-Invasive Screening Options

While histopathology remains the gold standard, serum biomarkers can suggest atrophic gastritis and guide the decision for endoscopy: 2, 3, 4

  • Low pepsinogen I and/or low pepsinogen I/II ratio: indicates corpus atrophy
  • High fasting gastrin-17: suggests corpus-predominant atrophy (autoimmune)
  • Low gastrin-17: suggests antral atrophy or high gastric acidity
  • H. pylori antibodies: reliable even in patients with atrophy and hypochlorhydria

However, the AGA guidelines suggest against routine gastric biopsies solely to diagnose atrophic gastritis in iron deficiency anemia patients without other indications. 1 These biomarkers are more useful in research settings or high-risk populations.

Risk Stratification

Once atrophic gastritis is confirmed, assess the extent using staging systems: 5, 6

  • OLGA system (Operative Link for Gastritis Assessment): combines antral and body atrophy scores
  • OLGIM system: focuses on intestinal metaplasia distribution
  • Higher stages (III-IV) indicate significantly increased gastric cancer risk

Advanced atrophic gastritis is defined by both anatomic extent and histologic grade, warranting surveillance endoscopy every 3 years. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

How should atrophic gastritis be managed in an adult patient (typically over 50 years old), including diagnostic work‑up, Helicobacter pylori eradication, treatment of vitamin B12 or iron deficiency, symptom control with proton‑pump inhibitors, lifestyle modifications, and endoscopic surveillance?
What is the treatment for atrophic gastritis?
What is the management and treatment of atrophic conditions?
What are the causes of atrophic gastritis?
What is the appropriate management for antral gastritis identified during endoscopy?
Which is the better choice for systemic or nail fungal infections, Itrovance (oral itraconazole) or Conazit (topical itraconazole)?
Which part of the inguinal region should be clipped before a groin arterial or venous access procedure?
In a patient with recurrent ischemic stroke who is on dual anticoagulant therapy, what is the recommended duration of ticagrelor (Brilinta) treatment?
What is the appropriate emergency and subsequent management for a patient who attempted hanging?
What is the step‑by‑step procedure for rapid sequence intubation in an adult patient who requires immediate airway control and cannot be safely ventilated with bag‑mask techniques?
In a 68‑year‑old obese male (BMI ≈34 kg/m²) two weeks after left posterior total hip arthroplasty with a dry, pruritic skin fold over the incision, what is the risk of developing postoperative cellulitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question